Patents by Inventor Philip J. Barr

Philip J. Barr has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5853739
    Abstract: The present invention relates to transmission-blocking vaccines against malaria. Vaccines of the present invention contain a recombinant Pfs25 Plasmodium falciparum protein produced by yeast cells and to yeast cells producing the protein. Mice and monkeys inoculated with the yeast-expressed Pfs25 of the present invention have developed antibodies with transmission-blocking activity. The present invention also relates to methods of preventing or treating malarial infections using the vaccines of the present invention.
    Type: Grant
    Filed: December 29, 1994
    Date of Patent: December 29, 1998
    Assignees: The United States of America as represented by the Department of Health and Human Services, Chiron Corporation
    Inventors: David C. Kaslow, Philip J. Barr
  • Patent number: 5792463
    Abstract: Novel immunogenic compositions are provided involving viral particles composed at least in part of hybrid proteins of at least a portion of a particle forming protein and one or more polypeptides having at least one epitope of interest. Nucleic acid sequences are employed coding for the hybrid protein which are introduced into a host cell for expression, either by themselves or in combination with other DNA sequences coding for particle forming proteins. Expression of the DNA sequences results in formation of particles which may be isolated and used as immunogens for production of antibodies for diagnostics purposes, passive immunization, vaccination, or other uses.Saccharomyces carlsbergensis, 2150-2-3 (pDC103), was deposited on Sep. 7, 1984, at the ATCC and given ATCC Accession No. 20726. Also, Saccharomyces cerevisiae PO17 (pC1/1-MCS29) was deposited at the ATCC on Sep. 5, 1985, and given ATCC Accession No. 20770.
    Type: Grant
    Filed: December 9, 1994
    Date of Patent: August 11, 1998
    Assignee: Chiron Corporation
    Inventors: Pablo D. T. Valenzuela, George Kuo, Philip J. Barr
  • Patent number: 5770443
    Abstract: The present invention provides a novel family of apoptosis-modulating proteins. Nucleotide and amino acid residue sequences and methods of use thereof are also provided.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: June 23, 1998
    Assignee: LXR Biotechnology Inc.
    Inventors: Michael C. Kiefer, Philip J. Barr
  • Patent number: 5759548
    Abstract: The present invention is to methods of obtaining plant-derived compositions that inhibit apoptosis, the compositions obtained thereby, compositions comprising the composition, and methods of use thereof.
    Type: Grant
    Filed: October 7, 1994
    Date of Patent: June 2, 1998
    Assignee: LXR Biotechnology Inc.
    Inventors: Ian C. Bathurst, John D. Bradley, L. David Tomei, Philip J. Barr
  • Patent number: 5663070
    Abstract: The invention provides soluble forms of the Fas (Apo-1 ) protein comprising both the intracellular and extracellular domains of the full-length polypeptide. Exemplified is a naturally-occurring splice variant of the Fas gene, Fas.DELTA.TM, which lacks the transmembrane domain of the native antigen. DNA encoding the protein, cells expressing the recombinant DNA, and methods of using the protein and DNA are also provided.
    Type: Grant
    Filed: November 15, 1993
    Date of Patent: September 2, 1997
    Assignee: LXR Biotechnology Inc.
    Inventors: Philip J. Barr, John P. Shapiro, Michael C. Kiefer
  • Patent number: 5656458
    Abstract: Methods and compositions are provided for producing, in yeast, basic and acidic fibroblast growth factors (FGF's) that are at least partially acetylated at their amino-termini. DNA constructs containing genes coding for the FGF polypeptides under transcriptional control of a regulatable promoter are expressed in transformed host yeast cells to achieve high yields of the processed FGF's.
    Type: Grant
    Filed: June 29, 1994
    Date of Patent: August 12, 1997
    Assignee: Chiron Corporation
    Inventor: Philip J. Barr
  • Patent number: 5652210
    Abstract: The invention provides soluble forms of the Fas (Apo-1) protein comprising both the intracellular and extracellular domains of the full-length polypeptide. Exemplified is a naturally-occurring splice variant of the Fas gene, Fas.DELTA.TM, which lacks the transmembrane domain of the native antigen. DNA encoding the protein, cells expressing the recombinant DNA, and methods of using the protein and DNA are also provided.
    Type: Grant
    Filed: May 18, 1995
    Date of Patent: July 29, 1997
    Assignee: LXR Biotechnology, Inc.
    Inventors: Philip J. Barr, John P. Shapiro, Michael C. Kiefer
  • Patent number: 5635374
    Abstract: The isolation, identification and production by recombinant methods of bone calcification factor, a 22 KD polypeptide, are disclosed. The peptide has calcification-inducing activity when implanted with matrix Gla protein into mammals.
    Type: Grant
    Filed: May 4, 1994
    Date of Patent: June 3, 1997
    Assignee: Chiron Corporation
    Inventors: Michael C. Kiefer, Frank R. Masiarz, Philip J. Barr
  • Patent number: 5635187
    Abstract: The present invention is directed to methods of obtaining plant-derived delipidated extracts that inhibit apoptosis, the extracts obtained, compositions containing said extracts and methods of using said compositions. FIG. 11 is a bar graph which illustrates a lower incidence of diarrhea in rats treated with methotrexate and fed a diet of compositions of the claimed invention as compared to controls.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: June 3, 1997
    Assignee: LXR Biotechnology Inc.
    Inventors: Ian C. Bathurst, John D. Bradley, L. David Tomei, Philip J. Barr
  • Patent number: 5635186
    Abstract: The present invention is to methods of obtaining plant-derived compositions that inhibit apoptosis, the compositions obtained thereby, compositions comprising the composition, and methods of use thereof.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: June 3, 1997
    Assignee: LXR Biotechnology Inc.
    Inventors: Ian C. Bathurst, John D. Bradley, L. David Tomei, Philip J. Barr
  • Patent number: 5624672
    Abstract: The present invention is directed to methods of obtaining plant-derived delipidated extracts that inhibit apoptosis, the extracts obtained, compositions containing said extracts and methods of using said compositions. The figure is a bar graph which illustrates a lower incidence of diarrhea in rats treated with methotrexate and fed a diet of compositions of the claimed invention as compared to controls.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: April 29, 1997
    Assignee: LXR Biotechnology Inc.
    Inventors: Ian C. Bathurst, John D. Bradley, L. David Tomei, Philip J. Barr
  • Patent number: 5620867
    Abstract: The purification and cloning of bone morphogenetic proteins are disclosed, as well as production of BMP and its analogs thereof by recombinant DNA techniques. Pharmaceutical compositions comprising BMP and the use of such compositions are also disclosed.
    Type: Grant
    Filed: October 26, 1993
    Date of Patent: April 15, 1997
    Assignee: Chiron Corporation
    Inventors: Michael C. Kiefer, Frank R. Masiarz, Philip J. Barr
  • Patent number: 5620885
    Abstract: The present invention is to methods of obtaining plant-derived compositions that-inhibit apoptosis, the compositions obtained thereby, compositions comprising the composition, and methods of use thereof.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: April 15, 1997
    Assignee: LXR Biotechnology Inc.
    Inventors: Ian C. Bathurst, John D. Bradley, L. David Tomei, Philip J. Barr
  • Patent number: 5567425
    Abstract: The present invention is to methods of obtaining plant-derived compositions that inhibit apoptosis, the compositions obtained thereby, compositions comprising the composition, and methods of use thereof.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: October 22, 1996
    Assignee: LXR Biotechnology Inc.
    Inventors: Ian C. Bathurst, John D. Bradley, L. David Tomei, Philip J. Barr
  • Patent number: 5523390
    Abstract: Provide herein is a substantially pure gingipain-1 preparation, gingipain-1 being characterized as having an apparent molecular mass of 50 kDa as estimated by sodium dodecyl sulfate polyacrylamide gel electrophoresis and an apparent molecular mass of 44 kDa as estimated by gel filtration chromatography, said gingipain-1 having amidolytic and proteolytic activity for cleavage after arginine residues and having no amidolytic and/or proteolytic activity for cleavage after lysine residues, wherein the amidolytic and/or proteolytic activity is inhibited by cysteine protease group-specific inhibitors including iodoacetamide, iodoacetic acid, N-ethylmaleimide, leupeptin, antipain, trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane, TLCK, TPCK, p-aminobenzamidine, N-chlorosuccinamide, and chelating agents including EDTA and EGTA, wherein the amidolytic and/or proteolytic activity of said gingipain-1 is not sensitive to inhibition by human cystatin C, .alpha.2-macroglobulin, .alpha.
    Type: Grant
    Filed: September 10, 1993
    Date of Patent: June 4, 1996
    Assignee: University of Georgia Research Foundation, Inc.
    Inventors: James Travis, Jan S. Potempa, Philip J. Barr, Nadine Pavloff
  • Patent number: 5475097
    Abstract: Provide herein is a substantially pure Lys-gingipain complex preparation, Lys-gingipain being characterized as having an apparent molecular mass of 105 kDa as estimated by sodium dodecyl sulfate polyacrylamide gel electrophoresis, where sample is prepared without boiling, said Lys-gingipain having amidolytic and proteolytic activity for cleavage after lysine residues and having no amidolytic and/or proteolytic activity for cleavage after arginine residues, wherein the amidolytic and/or proteolytic activity is inhibited by TLCK, cysteine protease group-specific inhibitors including iodoacetamide and iodoacetic acid, wherein the amidolytic and/or proteolytic activity of said Lys-gingipain is not sensitive to inhibition by leupeptin, antipain, trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane, serine protease group-specific inhibitors including diisopropylfluorophosphate and phenylmethyl sulfonylfluoride, and antibodies specific for the Lys-gingipain protein complex and its catalytic component, methods for p
    Type: Grant
    Filed: October 21, 1993
    Date of Patent: December 12, 1995
    Assignee: University of Georgia Research Foundation, Inc.
    Inventors: James Travis, J. Stanislaw Potempa, Philip J. Barr, Nadine Pavloff, Robert N. Pike
  • Patent number: 5460950
    Abstract: Compositions and methods are provided for endopeptidase production and for enhanced efficiencies of processing heterologous precursor polypeptides to mature polypeptides, including proteins requiring gamma-carboxylation for biological activity. These compositions and methods utilize recombinant PACE, a mammalian endopeptidase that is specific for dibasic amino acid sites.
    Type: Grant
    Filed: May 20, 1992
    Date of Patent: October 24, 1995
    Assignees: Genetics Institute, Inc., Chiron Corporation
    Inventors: Philip J. Barr, Anthony J. Brake, Randal J. Kaufman, Louise Wasley, Patricia Tekamp-Olson, Polly A. Wong
  • Patent number: 5229501
    Abstract: A new receptor for fibroblast growth factor has been cloned and expressed. The recombinant receptor is useful for inhibiting FGF activity, and for screening compounds for binding activity similar to that of FGF. A soluble, truncated recombinant receptor is also prepared, and is capable of binding FGF.
    Type: Grant
    Filed: January 11, 1991
    Date of Patent: July 20, 1993
    Assignee: Chiron Corporation
    Inventors: Michael C. Keifer, Pablo D. T. Valenzuela, Philip J. Barr
  • Patent number: 5217898
    Abstract: The present invention relates to transmission-blocking vaccines against malaria. Vaccines of the present invention contain a recombinant Pfs25 Plasmodium falciparum protein produced by yeast cells and to yeast cells producing the protein. Mice and monkeys inoculated with the yeast-expressed Pfs25 of the present invention have developed antibodies with transmission-blocking activity. The present invention also relates to methods of preventing or treating malarial infections using the vaccines of the present invention.
    Type: Grant
    Filed: May 8, 1991
    Date of Patent: June 8, 1993
    Assignees: The United States of America as represented by the Secretary of Health and Human Services, Chiron Corporation
    Inventors: David C. Kaslow, Philip J. Barr
  • Patent number: 5096825
    Abstract: A DNA having a base sequence coding for human epidermal growth factor has been synthesized in blocks, and cloned. Novel recombinant DNA transfer vectors containing said cloned DNA have been constructed. The codon usage of the sequence reflects the codon bias of yeast. The DNA sequence is useful for the large scale synthesis of human epidermal growth factor in yeast cells or microorganisms transformed by said recombinant DNA transfer vectors.
    Type: Grant
    Filed: January 5, 1987
    Date of Patent: March 17, 1992
    Assignee: Chiron Corporation
    Inventors: Philip J. Barr, James P. Merryweather, Guy T. Mullenbach, Mickey S. Urdea, Pablo Valenzuela